Immunic, Inc. (NASDAQ:IMUX) Receives $12.25 Average Price Target from Analysts

Immunic, Inc. (NASDAQ:IMUX - Get Free Report) has earned an average rating of "Buy" from the six research firms that are covering the company, MarketBeat.com reports. Four analysts have rated the stock with a buy rating and two have issued a strong buy rating on the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $12.25.

Several brokerages recently issued reports on IMUX. EF Hutton Acquisition Co. I upgraded shares of Immunic to a "strong-buy" rating in a research note on Monday, September 16th. B. Riley started coverage on Immunic in a research note on Tuesday, August 27th. They set a "buy" rating and a $6.00 target price for the company. Leerink Partnrs raised Immunic to a "strong-buy" rating in a report on Monday, September 9th. Leerink Partners reaffirmed an "outperform" rating and set a $5.00 price target on shares of Immunic in a report on Monday, September 9th. Finally, StockNews.com lowered Immunic from a "hold" rating to a "sell" rating in a research note on Monday, November 11th.

Insider Buying and Selling at Immunic

In related news, Director Richard Alan Rudick bought 87,300 shares of the business's stock in a transaction dated Tuesday, November 12th. The stock was purchased at an average cost of $1.15 per share, for a total transaction of $100,395.00. Following the transaction, the director now owns 87,300 shares in the company, valued at $100,395. The trade was a ∞ increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 3.00% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. BVF Inc. IL acquired a new position in Immunic during the first quarter valued at approximately $11,752,000. Janus Henderson Group PLC bought a new position in shares of Immunic in the 1st quarter valued at $9,266,000. Vanguard Group Inc. raised its holdings in shares of Immunic by 100.7% during the 1st quarter. Vanguard Group Inc. now owns 3,394,047 shares of the company's stock worth $4,480,000 after buying an additional 1,703,047 shares in the last quarter. Ikarian Capital LLC lifted its position in shares of Immunic by 258.3% during the 1st quarter. Ikarian Capital LLC now owns 1,612,378 shares of the company's stock worth $2,128,000 after buying an additional 1,162,378 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. boosted its stake in Immunic by 70.8% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 102,257 shares of the company's stock valued at $169,000 after buying an additional 42,383 shares in the last quarter. Institutional investors and hedge funds own 51.82% of the company's stock.

Immunic Price Performance

IMUX stock traded down $0.01 during trading hours on Friday, reaching $1.10. The stock had a trading volume of 787,645 shares, compared to its average volume of 906,935. The stock has a 50-day simple moving average of $1.40 and a 200 day simple moving average of $1.34. Immunic has a fifty-two week low of $0.97 and a fifty-two week high of $2.11. The stock has a market capitalization of $99.09 million, a PE ratio of -0.89 and a beta of 1.88.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.